

Beatriz R. Olson M.D., FACP
415 Middlebury Road
Middlebury, CT 06702
203-758-2594 or Fax 203-758-2708

Polycystic Ovary Syndrome and Insulin Resistance: Whats New in 2002

References

- **Polycystic Ovary Syndrome and Insulin Resistance**
- Ovalle F Azziz Insulin Resistance, polycystic ovary syndrome, and type 2 diabetes. *Fertility Sterility* 77(6):1095-1105,2002 (review)
- Li M, Youngren JF, Dunaif A et.al. Decreased insulin receptor (IR) autophosphorilation in fibroblasts from patients with PCOS, effects of serine kinase inhibitors and IR activators. *JCEM* 2002 Sept 87(9):4088-93
- (reversible defect in insulin receptor that decreases IR autophosphorilation by 40% in fibroblasts of women with PCOS. Apperas that abnormal activation of a serine kinase activity affects the function of tyrosine kinase which is needed for normal insulin receptor phosphorilation
- Azziz R. Polycystic ovary syndrome, insulin resistance, and molecular defects in insulin signaling *JCEM* 2002 s *JCEM* 2002 Sept 87(9):4085-87
- Dunaif A Thomas A 2001 Current Concepts in polycystic ovary. *Ann Rev Med* 52:401-419
- Strowitzki T, Halser B, Demant T Body fat distribution insulin sensitivity ovarian dysfunction and serum lipoproteins in patients with PCOS *Gynecological Endocrinology* 16(1):45-51, 2002
- Magoffin DA. The ovarian androgen producing cell *Reviews in Endocrine & Metabolic disorders* 3(1):47-53, 2002

Demographics

- Legro R.S. Polycystic ovary syndrome. Long term sequelae and management. *Minerva Ginecologia* 54(2):97-114, 2002. Review.

Pathophysiology

- Peral B, San Millan JL, Castello et al. The methionine 196 arginine polymorphism in exon 6 of the TNF receptor 2 gene (TNFRSF1B) is associated with polycystic ovary syndrome and hyperandrogenism. *JCEM*(8):3977-83, 2002.
- Azziz et al Chronic hyperinsulinemia and adrenal androgen response to acute corticotropin(1-24) stimulation and hyperandrogenic women *Am J Obstetrics Gynecol* 172:1251-1256.
- Dunaif A 1997 Insulin resistance and the polycystic ovary syndrome : mechanisms and implication for pathogenesis *Endocrine Reviews* 18:774-800.
- Dunaif A. Wu X, Lee A, et al. Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome *Am J Physiol* 281:E392-E399, 2001

12/11/02

- Nestler JE Jakubowicz 1996 Decreases in ovarian cytochrome 450C17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome NEJM 335:617-23.
- Dunaif A, Scott D, Finegood D et al. The insulin sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome JCEM 81:3299-3306, 1996
- Nestler JE Jakubowicz DJ et al. 1999 Ovulatory and metabolic effect of D-chiro-inositol in polycystic ovary syndrome. NEJM 340:1314-1320, 1999.
- Zhang LH Rodriguez H, Ohno S, Miller WL 1995. Serine phosphorylation of human P450C17 increases 17,20 lyase activity; implications for adrenarche and the polycystic ovary syndrome. Proc Natl Acad Sci 92:10619-10623, 1995.
- Schoff C et al. Circulating Gherlin levels in women with PCOS JCEM 87(10):4607-10, 2002

Genetics and family studies

- Legro RS & Straus JF Molecular progress in infertility: Polycystic ovary syndrome. Fertility Sterility 78(3): 569-76, 2002
- Ehrman DA Polymorphism in IRS-2- J Clin Endo Metab 2002
- Gonzalez A Abril E, Roca A et.al. CAPN10 alleles are associated with PCOS J Clin Endocrinol Metab 87(8): 3971-6, 2002. This is a gene in the type 2 susceptibility locus
- Legro RS Kunselman AR, Demers L et al Elevated dehydroepiandrosterone sulfate levels as the reproductive phenotype in the brothers of women with polycystic ovary syndrome JCEM 87(5):2134-8, 2002. This study provides evidence for a genetic basis for susceptibility for PCOS 119 brothers of girls with PCOS have higher DHEAS levels than controls (68) 3035 ± 1135 ng/ml vs 2494 ± 1172 ng/ml. No increase in male pattern balding is detected.
- Legro RS Insulin resistance in sisters of women with polycystic ovary syndrome: association with hyperandrogenemia rather than menstrual irregularity JCEM 87(5):2128-33, 2002

Drugs are associated with PCOS

- Luef G Abraham I, Haslinger M et.al Polycystic ovary, obesity, and insulin resistance in women with epilepsy. A comparative study of carbamazepine and valproic acid. J Neurology 249(7):835-841, 2002
- O'Donovan et.al. Menstrual abnormalities and polycystic ovary in women taking valproate for bipolar mood disorder J Clin Psych 63(4):322-30,2002.

Cardiac risk markers

- Vribikova J et al Homocystein and steroid levels in metformin treated women with PCOS. Exp & clin endocrinol and Diabetes 110(2):74-6, 2002
- 9 women each her own control only 1 month therapy (low dose 1000mg)
- homocysteine increased from 10.1 ± 2.6 to 13.4 ± 5.1 mcg/L

12/11/02

- Yildiz BO et al, Global fibrinolytic capacity is decreased in Polycystic ovary syndrome, suggesting a prothrombotic state. JCEM 87(8):3871-5, 2002.
- Kelly CJ, Lyall H, Petrie JR et al A specific elevation in tissue plasminogen activator antigen in women with PCO. JCEM 87(7):3287-90,2002
- Loverro G, Lorusso F, Mei L et al. The plasma homocysteine levels re increased in polycystic ovary syndrome Gynecologic & Obstetric Investigation. 53(3):157-162,2002. 35 PCOS vs 20 healthy women. homocysteine levels 10.4+4.4 vs 7.2 + 1.5 mg/dl, P<0.003).
- Kelly CCJ, Lyall H Petrie Jr et al Low grade chronic inflammation in women with polycystic ovary syndrome JCEM 86:2453-2455 2001.
- Ibanez L et.al. Plasminogen activator inhibitor-1 in girls with precocious pubarche: a premenarchal marker for PCOS? Pediatric Research 51(2):244-8, 2002

Treatments

- Bagis T et..al. the effects of short term medroxyprogesterone acetate and micronized progesterone on glucose metabolism and lipid profiles in patients with PCOS: a prospective randomized trial J Clin Endo Metab 87(10):4536-40, 2002.
- Woods KS, Reyna R, Azziz R. Effect of micronized progesterone on androgen levels in women with PCOS Fertility Sterility 77(6):1125-7, 2002
- Randeve RS et.al. Exercise decreases plasma total homocysteine in overweight young women with polycystic ovary. JCEM 87(10):4496-501, 2002. 12 exerciser versus 9 non-exerciser obese PCOS, 6 month trial. Exercisers decreases their homocysteine levels, waist to hip ratio
- *Fulghesu AM, Ciampelli M, Muzj G et.al.N-acetyl-cysteine treatment improves insulin sensitivity in women with PCOS. Fertility Sterility 77(6): 1128-35, 2002. Prospective 6 control PCOS 24 treated dose 1.8, 3g in very obese. Androgen levels and insulin AUC improved in hyperinsulinemic pts.
- Hacıhanefioglu B et al. Effect of hypertension therapy with the ACE inhibitor lisinopril on hyperandrogenism in women with PCOS. Fertility Sterility 77(3):526-8, 2002.

Insulin sensitizing agent:

- Nestler JE, Stovall D, Akter N et al. Strategies for the use of insulin sensitizing drugs to treat infertility in women with polycystic ovary syndrome. Fertility Sterility 77(2): 209-15, 2002 (review)
- Fertility Sterility 78(2): 653-655, 2002
- Legro R.S. Polycystic ovary syndrome. Long term sequelae and management. Minerva Ginecologia 54(2):97-114, 2002. Review.
- Kelly CJ, Gordon D Effect of metformin on hirsutism in polycystic ovary syndrome. European Journal of Endocrinology 147(2):217-21. 2002
- Malkawi HY & Qublan HS The effect of Metformin plus clomiphene citrate on ovulation and pregnancy rates in clomiphene resistant women with polycystic ovary syndrome. Saudi Medical Journal 23(6):663-6, 2002. 16 Met 850 mg BID+CC vs 12 plac+CC, Met group increased ovulation rate 68.6% vs 25%, increased pregnancy rate 56.3% vs 16% (P<0.05)
- Kirpichnikov D, MCFarlane SI, Sowers JR. Metformin: An update. Annals of Internal Medicine. 137(1):25-33, 2002.

12/11/02

- Moghetti P et al. Metformin effects on Clinical features, Endocrine and Metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized placebo controlled 6-month trial, followed by open, long-term clinical evaluation. JCEM 85:139-146, 2000. (dose 500 mg tid,)

Psychological

- Trent ME, Rich M, Austin SB, Gordon CM. Quality of life in adolescent girls with polycystic ovary. Arch Peds and Adoles Med 156(6):556-60, 2002.

Controversies:

Should adolescents be treated for PCOS?

- Kent SE, Legro RS. Polycystic ovary in adolescents Adolescent medicine state of the art reviews 13(1): 73-88,vi, 2002
- Mulchahey KM. In support for metformin use in adolescent Polycystic ovary syndrome J Ped and Adolescent Gynecology 15(2): 109-111, 2002
- Trent M Metformin in adolescents with polycystic ovary syndrome: opposed. J Ped and Adolescent Gynecology 15(2): 111-114, 2002
- Arslanian SA et.al. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exgerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. JCEM 87:1555-1559,2002. Dose 850 bid 3 month treatment 15 obese adolescents with impaired glucose tolerance, 8 of the 15 had normal glucose tolerance at the end of the study.
- Homburg R. Should patients with polycystic ovary syndrome be treated with metformin? A note of cautious optimism (underscores lack of long term placebo controlled trials)- Human reproduction 17(4):853-6, 2002

Should pregnant women be maintained on Metformin once pregnant?

- Glueck CJ et.al. Metformin therapy throughout pregnancy reduces the development of gestational Diabetes in women with polycystic ovary syndrome Fertilit Sterility 77(3) :520-5, 2002.
- Jakubowics DJ, Luorno MJ, et al. Effects of Metformin in ovulation and pregnancy JCEM 2002